Concepedia

Author

Molly A. McGlynn

Pfizer (United States)

Also Known As

M McGlynn, Molly A McGlynn, Molly A. McGlynn

10

Publications

319

Citations

7

H-Index

15

Concepts

All Affiliations

Pfizer (United States)
MA

About

Molly A. McGlynn is an author at Pfizer (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

196

2

Pharmacology

5

5

196

3

Biochemistry

4

4

183

4

Natural Sciences

3

3

150

5

Behavioral Pharmacology

1

1

13

Molly A. McGlynn

×

6

Publications

285

Citations

6

H-Index

YearCitations

CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases

Ronald P. Gladue, Laurie Tylaska, William H. Brissette,

Journal of Biological Chemistry

2003

89

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity

Daniel P. Walker, Michael P. Zawistoski, Molly A. McGlynn,

Bioorganic & Medicinal Chemistry Letters

2009

86

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation

Daniel P. Walker, F. Christopher Bi, Amit S. Kalgutkar,

Bioorganic & Medicinal Chemistry Letters

2008

51

Novel CCR1 antagonists with improved metabolic stability

Matthew F. Brown, M P Avery, William H. Brissette,

Bioorganic & Medicinal Chemistry Letters

2004

33

Piperazinyl CCR1 antagonists—optimization of human liver microsome stability

Matthew F. Brown, Kevin B. Bahnck, Laura C. Blumberg,

Bioorganic & Medicinal Chemistry Letters

2007

13

Behavioral, biochemical, and pharmacological effects of chronic dosage of phenothiazine tranquilizers in rats.

R.P. Maickel, Braunstein Mc, Molly A. McGlynn,

PubMed

1974

13

Page 1